Coming September
For when a GLP alone is not enough
Eloralintide works a pathway the GLP medications do not touch, so it adds to one rather than replacing it. Deer launches it in September, paired with Retatrutide.
Launch list
Join the list for the combination programme. You will also get Deer news and offers, and can unsubscribe any time.
Research use only. Not approved by Health Canada, not prescribed, not covered by insurance.
Two signals, not one
GLP-1
What your pen works now
Amylin
What Eloralintide works
Together
Different signals, so they add up instead of repeating
Wherever you are, there is a step here
Most people never need the last one. It is here for the people who do.
SemaglutideFirst generation
~15%
TirzepatideSecond generation
~21%
RetatrutideThird generation
~28%
Eloralintide + RetatrutideCombination, September
Beyond
Percentages are average weight reduction at the top dose in each medication’s published trial, not a prediction. The combination has no published figure yet.
Safety comes first
Faster is not automatically better, so this one starts with a few conditions.
01
You will already be on Tirzepatide or Retatrutide
Eloralintide goes on top of a GLP, so the GLP is simply the first step.
02
A few questions when it opens
Your medication, your dose and how it is going, so we match the combination to you.
03
Not there yet? Start here
Between Semaglutide, Tirzepatide and Retatrutide there is something here for you today.
See the GLPs we sell today
These are our own conditions on the sale, not a medical assessment. Deer does not prescribe, so talk to a doctor about what suits you.
What the trial showed
Lilly’s 48-week phase 2 study in 263 adults: 9.5% to 20.1% average weight reduction across the dose arms, against 0.4% on placebo. Mostly mild nausea and fatigue. Phase 3 is underway.
- Class
- Selective amylin receptor agonist
- Dosing
- Once weekly, injected
- Trial
- Phase 2, 48 weeks, 263 adults
- Weight change
- 9.5% to 20.1% average, vs 0.4% placebo
- Published
- The Lancet, ObesityWeek 2025
- Status
- Investigational, phase 3 underway
Common questions
What is amylin?
A hormone your body releases with insulin that tells your brain you have eaten enough. Eloralintide targets that receptor. GLP medications work a different signal, which is why the two add up rather than doing the same job twice.
Why paired rather than on its own?
Because that is where it is strongest, and it is how Lilly is developing it. On its own it lands in GLP territory. On top of a GLP it goes further.
What will it cost?
Not set yet. It will be priced the way we price everything: the real cost of the medication, no membership, no consult fee.
Eloralintide is an investigational compound. It is not approved by Health Canada, and Deer products are sold for research purposes only. The figures on this page are averages from published trials and are not a prediction of individual results. Nothing here is medical advice, and Deer does not prescribe or provide clinical assessment. Eloralintide is a compound developed by Eli Lilly and Company, which is not affiliated with Deer.